Evidence and Insights: Making the Case for Greater CVD Risk Reduction was a satellite symposium at the AHA annual meeting in November 2006. The program brought together expert faculty in the area of cardiovascular disease (CVD) risk assessment, screening, and treatment to examine CVD risk factors and risk reduction.
The format included short presentations by faculty members followed by periods of discussion in an attempt to draw out key issues and controversies in the area of CVD risk reduction. A lively conversation between the faculty brought to light some interesting challenges in the context of primary and secondary CVD prevention: How useful is the Framingham Risk Assessment Tool, and what are the limitations that need to be considered? Is LDL-C the best marker for risk assessment and response to therapy in primary prevention? What other potential biomarkers may offer additional prognostic impact to the arena of primary and secondary CVD risk prevention?
This newsletter highlights some of the main points from each presentation and provides insights based on discussions throughout the program.
moderator |
|||
![]() |
Daniel J. Rader, MD |
||
speakers |
|||
![]() |
Roger S. Blumenthal, MD, FACC, FCCP, FAHA |
![]() |
Lori J. Mosca, MD, MPh, PhD |
![]() |
Allan D. Sniderman, MD |
![]() |
Christopher P. Cannon, MD |